Interest continues to grow in the use of microbes to produce cannabinoids.
Intrexon, an American biotech company listed on the Nasdaq stock exchange, has announced a development in its microbial platform capable of producing cannabinoids for medical use.
It has created a yeast strain capable of producing low-cost, robust and consistent cannabinoid outputs through fermentation.
Exectuve directive Chris Savile said: “Microbial fermentation routes to produce cannabinoids provide advantages over traditional plant-based extraction. We expect to optimise strains to produce specific cannabinoids that may be commercialised in the coming years.”
Get access to premium content that is normally only available for subscribers. For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.